Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by ...
LOS ANGELES--(BUSINESS WIRE)--Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical ...
First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. This is an ASCO ...
Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment ...
The TGFβ superfamily's activins and inhibins are best recognized for controlling reproductive physiology. Diseases such as neurological problems and reproductive disorders like polycystic ovary ...
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback